Berotralstat and Defactinib: Interaction Details
- Berotralstat
- Orladeyo
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Berotralstat and Defactinib interaction:
Defactinib
We don't have a drug information page for Defactinib yet. Have a question about Defactinib? Ask a pharmacist, free →
What Happens When You Take Berotralstat With Defactinib
What can happen when they are taken together (rated Major)
Increased defactinib exposure and an increased risk of defactinib-related adverse effects
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Defactinib is a , and it should not be combined with strong or moderate . Giving defactinib together with such inhibitors raises defactinib exposure, which could heighten the risk of adverse reactions to defactinib.
A drug interaction study tested defactinib with itraconazole (a strong CYP3A ) at 200 mg daily for 10 days. Under these conditions, defactinib rose 2.2-fold and rose 3.9-fold. For the M4 , AUC rose 2.2-fold while Cmax fell by 6.8%.1
The Berotralstat and Defactinib Interaction, Explained
Berotralstat (Orladeyo) is taken to prevent hereditary angioedema attacks. Defactinib is a cancer medicine that your body breaks down mainly using an enzyme called . Berotralstat can slow down that enzyme, so defactinib may build up in your body and raise the chance of side effects from it.
The size of this effect was shown with a different, strong enzyme blocker, so exact numbers for berotralstat aren't known. Please don't stop or change either medicine on your own. Talk with your pharmacist or doctor, who can review your options and watch you closely.
Mechanism: Berotralstat inhibits , the pathway that metabolizes defactinib (CYP3A4 ). Expect increased defactinib exposure and a higher risk of defactinib adverse reactions.
- Magnitude (reference data): with itraconazole (strong ), defactinib rose 2.2-fold and 3.9-fold. M4 AUC rose 2.2-fold, Cmax fell 6.8%. The effect of berotralstat itself was not quantified in this data.
- Onset: unspecified. Evidence: probable. Severity: major.
- Management: labeling advises avoiding with strong or moderate CYP3A . If the combination is unavoidable, individualize therapy and monitor closely for defactinib toxicity.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Berotralstat and Defactinib Interact
The likely mechanism
of -mediated of defactinib
How to Manage the Berotralstat and Defactinib Interaction
The documented advice is to avoid using these two medicines together when possible, because defactinib levels can rise and cause more side effects.
- Don't stop or change either medicine on your own. Contact your prescriber or pharmacist first.
- Your care team may look at alternatives or, if the combination is needed, individualize your treatment and monitor you more closely.
- Tell them about all medicines and supplements you take, and report any new or worsening side effects promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Berotralstat or Defactinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: AVMAPKI FAKZYNJA CO-PACK oral capsules, tablets, avutometinib oral capsules, defactinib oral tablets
In a drug interaction study, of defactinib with itraconazole (a strong ) at 200 mg daily for 10 days raised the defactinib 2.2-fold and the 3.9-fold. For N-desmethyl amide (M4), the major of defactinib, the AUC rose 2.2-fold while the Cmax fell by 6.8%.1
Berotralstat and Defactinib: Common Questions
How serious is the Berotralstat and Defactinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Berotralstat and Defactinib interaction managed?
The documented advice is to avoid using these two medicines together when possible, because defactinib levels can rise and cause more side effects. Don't stop or change either medicine on your own. Contact your prescriber or pharmacist first. Your care team may look at alternatives or, if the combination is needed, individualize your treatment and monitor you more closely. Tell them about all medi… Management is individual — always follow your own care team's guidance.
Does taking Berotralstat and Defactinib at different times of day help?
No. Taking them at different times of day does not prevent this one. Berotralstat slows , an enzyme that breaks down defactinib, so defactinib can build up in the body. That change lasts while berotralstat is being taken and can continue for a while after the last dose.
Your pharmacist or prescriber can tell you how they will manage it.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Berotralstat and Defactinib Interaction
Ask in your own words about taking Berotralstat and Defactinib together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: AVMAPKI(TM) FAKZYNJA(TM) CO-PACK oral capsules, tablets, avutometinib oral capsules, defactinib oral tablets. Verastem, Inc (per manufacturer), Needham, MA, 2025. DailyMed
Other Serious Interactions of Berotralstat and Defactinib
Also serious with Berotralstat
- ColchicineContraindicated
- FlibanserinContraindicated
- LomitapideContraindicated
- Acetaminophen and CodeineMajor
Also serious with Defactinib
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.